Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy
Yi Zhang, Hu Zhou, Qike Zhang, Qingchi Liu et autres
0 citationsHematological Oncology
Zhijian Xiao
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
269Publications signalées
2879Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesKruppel-like factors research
Publications récentes
Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms
Zefei Bao, Bing Li, Tiejun Qin, Zefeng Xu et autres
0 citationsBlood Cancer Journal
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study
Zefeng Xu, Jinqin Liu, Zhenya Hong, Qingsong Yin et autres
0 citationsBlood Cancer Journal
Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation
Linlin Liu, Bing Li, Tiejun Qin, Zefeng Xu et autres
0 citationsHematological Oncology
Evaluating Systematic Uncertainty in Natural Gas Composition Inversion Models Using the GUM Framework and Monte Carlo Methods (MCM)
Jianmin Gao, Rui Hu, Zheng Zhao, Jin Zhang et autres
0 citationsSSRN Electronic Journal
Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development
Jingyuan Tong, Di Wang, Haoze Song, Ting Sun et autres
2 citationsAdvanced Science
The dynamic alterations of DDX41 mutations in patients with myelodysplastic neoplasms treated with lenalidomide
Junyun Liu, Yuwei Tang, Tiejun Qin, Bing Li et autres
1 citationLeukemia & lymphoma/Leukemia and lymphoma
1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup
Yujiao Jia, Haoxu Wang, Bingqing Huang, Qin Li et autres
0 citationsBlood
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
Guillermo Garcia‐Manero, Uwe Platzbecker, Pierre Fenaux, G. Roboz et autres
7 citationsBlood
Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients
Lijuan Chen, Na Gao, Wei Yang, Qike Zhang et autres
1 citationBlood
Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure
Yi Zhang, Hu Zhou, Qike Zhang, Qingchi Liu et autres
0 citationsBlood
PLENARY SESSION 05: MDS CLASSIFICATION IN 2025
Xiuli Wang, S.N. Qi, Xu Zhao, Shiqiang Qu et autres
0 citationsLeukemia Research
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.